Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy

被引：0

作者：

Merkel, Madeline ^{[1
]}

Grogan, Martha ^{[2
]}

Hawkins, Philip N. ^{[3
]}

Kristen, Arnt V. ^{[4
]}

Berk, John L. ^{[5
]}

Suhr, Ole B. ^{[6
]}

Lin, Hollis ^{[1
]}

McManus, Anastasia ^{[1
]}

Powell, Christine ^{[1
]}

Vest, John ^{[1
]}

Karsten, Verena ^{[1
]}

Judge, Daniel P. ^{[7
]}

机构：

[1] Alnylam Pharmaceut, Cambridge, MA USA

[2] Mayo Clin, Rochester, MN USA

[3] Royal Free Hosp, NAC, London, England

[4] Heidelberg Univ Hosp, Heidelberg, Germany

[5] Boston Univ, Boston, MA 02215 USA

[6] Umea Univ, Umea, Sweden

[7] Med Univ South Carolina, Columbia, SC USA

来源：

NEUROLOGY | 2020年 / 94卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

240

引用

下载

页数：4

共 50 条

[41] Cardiovascular burden prior to diagnosis of hereditary transthyretin-mediated amyloidosis
Llonch, M. V.
Ortiz-Perez, J. T.
Reddy, S. R.
Chang, E.
Tarbox, M. H. Marian
Pollock, M. R.
Nativi-Nicolau, J.
Fine, N. M.
EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 173 - 174
[42] Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis
Kristen, Arnt, V
Ajroud-Driss, Senda
Conceicao, Isabel
Gorevic, Peter
Kyriakides, Theodoros
Obici, Laura
NEURODEGENERATIVE DISEASE MANAGEMENT, 2019, 9 (01) : 5 - 24
[43] Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
Isabel Conceição
John L. Berk
Markus Weiler
Pedro A. Kowacs
Noel R. Dasgupta
Sami Khella
Chi-Chao Chao
Shahram Attarian
T. Jesse Kwoh
Shiangtung W. Jung
Jersey Chen
Nicholas J. Viney
Rosie Z. Yu
Morie Gertz
Ahmad Masri
Márcia Waddington Cruz
Teresa Coelho
Journal of Neurology, 2025, 272 (2)
[44] The V122I mutation in hereditary transthyretin-mediated amyloidosis is significantly associated with an increased incidence of polyneuropathy
Parker, M. M.
Damrauer, S. M.
Erbe, D.
Aldinc, E.
Ticau, S.
Flynn-Carroll, A.
Deaton, A. M.
Ward, L. D.
Rader, D. J.
Fitzgerald, K.
Vaishnaw, A. K.
Hinkle, G.
Nioi, P.
EUROPEAN HEART JOURNAL, 2020, 41 : 3143 - 3143
[45] Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients with Hereditary Transthyretin-Mediated Amyloidosis
Gonzalez-Duarte, Alejandra
Judge, Daniel P.
Dispenzieri, Angela
Lin, Hollis
Merkel, Madeline
Wang, Yue
Polydefkis, Michael
NEUROLOGY, 2020, 94 (15)
[46] Impact of Patisiran, an RNAi Therapeutic, on Diarrhea Symptoms in Patients With Hereditary Transthyretin-Mediated Amyloidosis
Obici, Laura
Gonzalez-Duarte, Alejandra
Waddington-Cruz, Marcia
Lin, Hollis
Merkel, Madeline
Wang, Yue
Ueda, Mitsuharu
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1657 - S1657
[47] Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients with Hereditary Transthyretin-Mediated Amyloidosis
Judge, Daniel P.
Gonzalez-Duarte, Alejandra
Dispenzieri, Angela
Lin, Hollis
Merkel, Madeline
Wang, Yue
Polydefkis, Michael
JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S78 - S78
[48] Hereditary transthyretin-mediated amyloidosis masquerading as diabetic neuropathy and lumbar radiculopathy
Horiuchi, Kohei
Hortelano, Chiara
Nikfar, Reza
Fogel, Joyce
BMJ CASE REPORTS, 2024, 17 (09)
[49] THE V122I MUTATION IN HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IS SIGNIFICANTLY ASSOCIATED WITH AN INCREASED INCIDENCE OF POLYNEUROPATHY
Parker, Margaret
Damrauer, Scott
Erbe, David
Aldinc, Emre
Ticau, Simina
Flynn-Caroll, Alexander
Deaton, Aimee
Ward, Lucas
Rader, Daniel
Fitzgerald, Kevin
Vaishnaw, Akshay
Hinkle, Gregory
Nioi, Paul
MUSCLE & NERVE, 2020, 62 : S107 - S107
[50] Alnylam Act®: Heterogenous Disease Manifestations of Hereditary Transthyretin-Mediated Amyloidosis
Malladi, Ruthvik
Truty, Rebecca
Winder, Tom
Dinh, Quinn
Melanson, Maria
Agarwal, Sonalee
JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S111 - S112

← 1 2 3 4 5 →